CL2020003354A1 - Compuestos - Google Patents
CompuestosInfo
- Publication number
- CL2020003354A1 CL2020003354A1 CL2020003354A CL2020003354A CL2020003354A1 CL 2020003354 A1 CL2020003354 A1 CL 2020003354A1 CL 2020003354 A CL2020003354 A CL 2020003354A CL 2020003354 A CL2020003354 A CL 2020003354A CL 2020003354 A1 CL2020003354 A1 CL 2020003354A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- manufacture
- pharmaceutical compositions
- active substances
- provides compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona compuestos que son inhibidores alostéricos selectivos de mutantes de EGFR que contienen T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S, su fabricación, composiciones farmacéuticas que los contienen y su utilización como sustancias terapéuticamente activas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18180758 | 2018-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020003354A1 true CL2020003354A1 (es) | 2021-07-19 |
Family
ID=62837714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020003354A CL2020003354A1 (es) | 2018-06-29 | 2020-12-22 | Compuestos |
Country Status (20)
Country | Link |
---|---|
US (1) | US20210079005A1 (es) |
EP (1) | EP3814351A1 (es) |
JP (1) | JP7411588B2 (es) |
KR (1) | KR20210025535A (es) |
CN (1) | CN112437774A (es) |
AR (1) | AR115663A1 (es) |
AU (1) | AU2019294414B2 (es) |
BR (1) | BR112020026450A2 (es) |
CA (1) | CA3103166A1 (es) |
CL (1) | CL2020003354A1 (es) |
CR (1) | CR20200625A (es) |
IL (1) | IL279800B2 (es) |
MA (1) | MA53003A (es) |
MX (1) | MX2020014085A (es) |
PE (1) | PE20211388A1 (es) |
PH (1) | PH12020552154A1 (es) |
SG (1) | SG11202011818YA (es) |
TW (1) | TWI833773B (es) |
WO (1) | WO2020002487A1 (es) |
ZA (1) | ZA202007956B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI3986897T3 (fi) * | 2019-06-21 | 2023-10-20 | Hoffmann La Roche | Egfr-estäjä syövän hoitoon |
WO2020254546A1 (en) * | 2019-06-21 | 2020-12-24 | F. Hoffmann-La Roche Ag | New egfr inhibitors |
CN114901277B (zh) | 2019-12-20 | 2024-05-17 | C4医药公司 | 用于egfr降解的异吲哚啉酮和吲唑化合物 |
US20240002390A1 (en) * | 2020-12-01 | 2024-01-04 | Hoffmann-La Roche Inc. | New indazole acetylene derivatives |
US20240018154A1 (en) * | 2020-12-01 | 2024-01-18 | Hoffmann-La Roche Inc. | New indazole derivatives |
JP2023551769A (ja) * | 2020-12-01 | 2023-12-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
BR112023024507A2 (pt) * | 2021-05-26 | 2024-02-15 | C4 Therapeutics Inc | Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central |
WO2023283130A1 (en) | 2021-07-04 | 2023-01-12 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
KR20240112819A (ko) | 2021-09-30 | 2024-07-19 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 피롤로벤조디아제핀 유도체 및 이의 접합체, 이의 제조 방법 및 이의 응용 |
WO2024151741A1 (en) * | 2023-01-11 | 2024-07-18 | Dana-Farber Cancer Institute, Inc. | Mutant-selective egfr inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2034996A2 (en) * | 2006-05-25 | 2009-03-18 | Synta Pharmaceuticals Corporation | Triazole compounds that modulate hsp90 activity |
JP2011525927A (ja) | 2008-06-25 | 2011-09-29 | シェーリング コーポレイション | 複素環式抗菌剤の合成および使用 |
US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
CA2985348C (en) | 2015-05-14 | 2023-10-24 | The Wistar Institute Of Anatomy And Biology | Ebna1 inhibitors and methods using same |
AU2016288204B2 (en) * | 2015-06-30 | 2020-11-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of EGFR and methods of use thereof |
TW201834651A (zh) | 2016-12-22 | 2018-10-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
WO2018220149A1 (en) * | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Compounds |
-
2019
- 2019-06-27 IL IL279800A patent/IL279800B2/en unknown
- 2019-06-27 WO PCT/EP2019/067111 patent/WO2020002487A1/en active Application Filing
- 2019-06-27 BR BR112020026450-4A patent/BR112020026450A2/pt not_active Application Discontinuation
- 2019-06-27 CA CA3103166A patent/CA3103166A1/en active Pending
- 2019-06-27 JP JP2020573326A patent/JP7411588B2/ja active Active
- 2019-06-27 MX MX2020014085A patent/MX2020014085A/es unknown
- 2019-06-27 AU AU2019294414A patent/AU2019294414B2/en active Active
- 2019-06-27 CN CN201980043788.5A patent/CN112437774A/zh active Pending
- 2019-06-27 MA MA053003A patent/MA53003A/fr unknown
- 2019-06-27 CR CR20200625A patent/CR20200625A/es unknown
- 2019-06-27 SG SG11202011818YA patent/SG11202011818YA/en unknown
- 2019-06-27 EP EP19733493.1A patent/EP3814351A1/en active Pending
- 2019-06-27 KR KR1020207037595A patent/KR20210025535A/ko not_active Application Discontinuation
- 2019-06-27 PE PE2020002105A patent/PE20211388A1/es unknown
- 2019-06-28 TW TW108122864A patent/TWI833773B/zh active
- 2019-07-01 AR ARP190101843A patent/AR115663A1/es unknown
-
2020
- 2020-11-25 US US17/105,060 patent/US20210079005A1/en active Pending
- 2020-12-14 PH PH12020552154A patent/PH12020552154A1/en unknown
- 2020-12-18 ZA ZA2020/07956A patent/ZA202007956B/en unknown
- 2020-12-22 CL CL2020003354A patent/CL2020003354A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TWI833773B (zh) | 2024-03-01 |
AR115663A1 (es) | 2021-02-10 |
MX2020014085A (es) | 2021-03-09 |
AU2019294414A1 (en) | 2020-12-24 |
AU2019294414B2 (en) | 2023-06-29 |
PH12020552154A1 (en) | 2021-07-05 |
IL279800B1 (en) | 2023-10-01 |
KR20210025535A (ko) | 2021-03-09 |
WO2020002487A1 (en) | 2020-01-02 |
JP7411588B2 (ja) | 2024-01-11 |
CA3103166A1 (en) | 2020-01-02 |
JP2021529775A (ja) | 2021-11-04 |
ZA202007956B (en) | 2021-10-27 |
PE20211388A1 (es) | 2021-07-27 |
CR20200625A (es) | 2021-02-05 |
TW202019930A (zh) | 2020-06-01 |
SG11202011818YA (en) | 2020-12-30 |
IL279800A (en) | 2021-03-01 |
US20210079005A1 (en) | 2021-03-18 |
EP3814351A1 (en) | 2021-05-05 |
CN112437774A (zh) | 2021-03-02 |
MA53003A (fr) | 2021-05-05 |
BR112020026450A2 (pt) | 2021-03-23 |
IL279800B2 (en) | 2024-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020003354A1 (es) | Compuestos | |
ECSP20003147A (es) | Carboxamidas como moduladores de los canales de sodio | |
CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
CO2017002532A2 (es) | Indazoles sustituidos con bencilo como inhibidores de bub1 | |
CO2019013016A2 (es) | Inhibidores pirazólicos de magl | |
CL2018003265A1 (es) | Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
CL2019001336A1 (es) | Inhibidores de la magl. | |
CO2017011958A2 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
CL2021002503A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251) | |
ECSP19084085A (es) | Inhibidores pirazólicos de magl | |
CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
CO2020015747A2 (es) | Analogos de rapamicina y usos de los mismos | |
DOP2021000071A (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
DOP2021000021A (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
CL2021002182A1 (es) | Formulación de anticuerpos terapéuticos | |
CO2019013557A2 (es) | Compuestos |